Myriad Genetics (MYGN) Tops Q4 EPS by 3c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $5.85 -7.87%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $196.6 million versus the consensus estimate of $194.8 million.
GUIDANCE:
Myriad Genetics sees FY2024 EPS of $0.00-$0.05, versus the consensus of ($0.02). Myriad Genetics sees FY2024 revenue of $820-840 million, versus the consensus of $834 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Waystar Holding Corp. (WAY) Reports Q3 EPS of $0.44
- Ero Copper Corp. (ERO) Tops Q3 EPS by 14c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
